Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Oncolytics Biotech stock (ONCY)

Buy Oncolytics Biotech stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Oncolytics Biotech is a biotechnology business based in the US. Oncolytics Biotech shares (ONCY) are listed on the NASDAQ and all prices are listed in US Dollars.

Our top picks for where to buy Oncolytics Biotech stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Oncolytics Biotech stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ONCY. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Oncolytics Biotech stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Oncolytics Biotech stock price (NASDAQ: ONCY)

Use our graph to track the performance of ONCY stocks over time.

Oncolytics Biotech shares at a glance

Information last updated 2024-07-08.
Latest market close$1.02
52-week range$0.88 - $3.37
50-day moving average $1.08
200-day moving average $1.29
Wall St. target price$4.79
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.29

Is it a good time to buy Oncolytics Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oncolytics Biotech price performance over time

Historical closes compared with the close of $1.02 from 2024-07-11

1 week (2024-07-05) -0.97%
1 month (2024-06-13) -0.97%
3 months (2024-04-12) -10.53%
6 months (2024-01-12) -16.39%
1 year (2023-07-13) -67.52%
2 years (2022-07-13) 1.89%
3 years (2021-07-13) 2.48
5 years (2019-07-12) 1.58

Oncolytics Biotech financials

Gross profit TTM $0
Return on assets TTM -63.83%
Return on equity TTM -115.8%
Profit margin 0%
Book value $0.31
Market Capitalization $77.7 million

TTM: trailing 12 months

Oncolytics Biotech share dividends

We're not expecting Oncolytics Biotech to pay a dividend over the next 12 months.

Have Oncolytics Biotech's shares ever split?

Oncolytics Biotech's shares were split on a 10:95 basis on 24 May 2018. So if you had owned 95 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Oncolytics Biotech shares – just the quantity. However, indirectly, the new 850% higher share price could have impacted the market appetite for Oncolytics Biotech shares which in turn could have impacted Oncolytics Biotech's share price.

Oncolytics Biotech share price volatility

Over the last 12 months, Oncolytics Biotech's shares have ranged in value from as little as $0.883 up to $3.37. A popular way to gauge a stock's volatility is its "beta".

ONCY.US volatility(beta: 1.42)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncolytics Biotech's is 1.419. This would suggest that Oncolytics Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oncolytics Biotech overview

Oncolytics Biotech Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. .

Frequently asked questions

What percentage of Oncolytics Biotech is owned by insiders or institutions?
Currently 3.899% of Oncolytics Biotech shares are held by insiders and 1.921% by institutions.
When does the fiscal year end for Oncolytics Biotech?
Oncolytics Biotech's fiscal year ends in December.
Where is Oncolytics Biotech based?
Oncolytics Biotech's address is: 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5
What is Oncolytics Biotech's ISIN number?
Oncolytics Biotech's international securities identification number is: CA6823108759
What is Oncolytics Biotech's CUSIP number?
Oncolytics Biotech's Committee on Uniform Securities Identification Procedures number is: 682310875

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site